KennethHo-MingYuMD

Gastrointestinal Cancer, Hematologic Oncology

Associate Professor

Overview of Dr. Yu

Dr. Kenneth Yu is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from Johns Hopkins University School of Medicine and has been in practice 18 years. He specializes in gastrointestinal cancers including pancreatic neoplasms, liver and bile duct cancers, neuroendocrine cancers, stomach and esophageal cancers, and colorectal cancers. He directs an NIH-funded translationa research program, and has more than 80 publications and over 500 citings.

Office
160 East 53rd Street
New York, NY 10022
Book by Phone+1(440) 253-0174

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2002 - 2005
University of Pennsylvania Health SystemResidency, Internal Medicine, 1999 - 2002
Johns Hopkins University School of MedicineClass of 1999

Certifications & Licensure

NJ State Medical License 2019 - 2025
NY State Medical License 2010 - 2025
PA State Medical License 2000 - 2010
American Board of Internal Medicine Medical Oncology

Clinical Trials

Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma Start of enrollment: 2011 Nov 01
Completed
Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection Start of enrollment: 2014 Sep 12
Completed
Not Applicable
Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma Start of enrollment: 2016 Oct 01
Active, not recruiting
Not Applicable
Predicting Effective Therapy in Pancreatic Cancer Start of enrollment: 2017 Jan 24
Active, not recruiting
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma Start of enrollment: 2017 Oct 30
Recruiting
Join now to see all

Publications & Presentations

PubMed

1 citations
Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer.
Catherine A O'Connor, Emily Harrold, David Lin, Henry Walch, Andrea Gazzo
JAMA Oncology. 2024-11-01
Adjuvant Modified FOLFIRINOX for Resected Pancreatic Adenocarcinoma (PDAC): Clinical Insights and Genomic Features from a Large Contemporary Cohort.
Fergus Keane, Catherine O'Connor, Drew Moss, Joanne F Chou, Maria A Perry
Journal of the National Cancer Institute. 2024-10-26
1 citations
Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease.
Fergus Keane, Joanne F Chou, Henry Walch, Joshua Schoenfeld, Anupriya Singhal
Journal of the National Cancer Institute. 2024-09-01

Authored Content

Phase II Trial of Veliparib in Patients with Previously Treated BRCA-Mutated Pancreas Ductal Adenocarcinoma☆January 2018
Phase II Trial of Veliparib in Patients with Previously Treated BRCA-Mutated Pancreas Ductal Adenocarcinoma☆January 2018
Phase II Trial of Veliparib in Patients with Previously Treated BRCA-Mutated Pancreas Ductal Adenocarcinoma☆January 2018

Press Mentions

Blood Protein May Spot Pancreatic Cancer Early - US NewsJune 24th, 2015

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment